Oruka Therapeutics, Inc. (ORKA) Institutional Ownership

Ownership Summary

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has 141 institutional investors that have filed 13F reports for the period ending December 2025.

• Their combined ownership stood at 118.5% of outstanding shares in December 2025, up from 103.6% in September 2025.
• They increased total shares held in Oruka Therapeutics by 16.32% from the prior quarter, while the number of investors in ORKA increased 113.64% year over year.
• Among the 141 funds, 98 bought more Oruka Therapeutics shares, 18 sold down, and 25 held their ground.
• Combined, these investors held 52.23Mn shares in ORKA for December 2025, up by 7.33Mn shares quarter on quarter, and up 20.47Mn shares year over year.
• As of December 31, 2025, the biggest holder of Oruka Therapeutics is FMR LLC at 7.43Mn shares, representing 16.86% of shares outstanding.
• Leading buyers of Oruka Therapeutics shares for the quarter ending December 2025 were VANGUARD CAPITAL MANAGEMENT LLC (1.86Mn), PRICE T ROWE ASSOCIATES INC /MD/ (727.45K), Paradigm Biocapital Advisors LP (610.0K), Bellevue Group AG (507.01K), VANGUARD PORTFOLIO MANAGEMENT LLC (350.89K).
• The largest sellers of Oruka Therapeutics for the quarter ending December 2025 were Affinity Asset Advisors, LLC (302.67K), Cable Car Capital, LP (200.0K), Soleus Capital Management, L.P. (185.0K), Deep Track Capital, LP (127.31K), Barclays Plc (87.59K).
• Oruka Therapeutics's 10 largest shareholders as of December 2025 include FMR LLC (7.43Mn), Venrock Adviser, LLC (4.15Mn), Fairmount Funds Management LLC (3.71Mn), BlackRock, Inc. (3.53Mn), VIKING GLOBAL INVESTORS LP (2.67Mn), Paradigm Biocapital Advisors LP (2.32Mn), RTW INVESTMENTS, LP (2.06Mn), Deep Track Capital, LP (2.03Mn), Remedium Capital Partners, LLC (1.89Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.86Mn) per Business Quant data.